AAV9

SOUTH SAN FRANCISCO, Calif., June 2, 2026 Tenaya Therapeutics announced that it will present new interim clinical data from...

SOUTH SAN FRANCISCO, Calif. – May 13, 2026 Encoded Therapeutics presented expanded clinical data from its ongoing POLARIS Phase...

NOVATO, Calif., April 2, 2026 Ultragenyx Pharmaceutical Inc. has reached a significant regulatory milestone as the U.S. Food and...

NOVATO, Calif., February 3, 2026 — Ultragenyx Pharmaceutical Inc. has reported positive long-term clinical data for UX111, an investigational...

NEW YORK—Nov. 12, 2025—Neurogene Inc. reported positive interim data from the pediatric cohort of its Phase 1/2 trial evaluating...

DALLAS, Oct. 2, 2025 — The U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to TSHA-102,...